RESUMO
Oseltamivir carboxylate is a potent and specific inhibitor of influenza A and B neuraminidase (NA). Oseltamivir phosphate, the ethyl ester prodrug of oseltamivir carboxylate, is the first orally active NA inhibitor available for the prophylaxis and treatment of influenza A and B. It offers an improvement over amantadine and rimantadine which are active only against influenza A and rapidly generate resistant virus. The emergence of virus resistant to oseltamivir carboxylate in the treatment of naturally acquired influenza infection is low (about 1%). The types of NA mutation to arise are sub-type specific and largely predicted from in vitro drug selection studies. A substitution of the conserved histidine at position 274 for tyrosine in the NA active site has been selected via site directed mutagenesis, serial passage in culture under drug pressure in H1N1 and during the treatment of experimental H1N1 infection in man. Virus carrying H274Y NA enzyme selected in vivo has reduced sensitivity to oseltamivir carboxylate. The replicative ability in cell culture was reduced up to 3 logs, as was infectivity in animal models of influenza virus infection. Additionally, pathogenicity of the mutant virus is significantly compromised in ferret, compared to the corresponding wild type virus. Virus carrying a H274Y mutation is unlikely to be of clinical consequence in man.
Assuntos
Acetamidas/farmacologia , Antivirais/farmacologia , Vírus da Influenza A Subtipo H1N1 , Vírus da Influenza A/efeitos dos fármacos , Mutação/efeitos dos fármacos , Neuraminidase/genética , Acetamidas/química , Acetamidas/uso terapêutico , Substituição de Aminoácidos , Animais , Antivirais/química , Antivirais/uso terapêutico , Peso Corporal , Linhagem Celular , Modelos Animais de Doenças , Farmacorresistência Viral/genética , Furões , Febre/etiologia , Humanos , Técnicas In Vitro , Inflamação/etiologia , Vírus da Influenza A/enzimologia , Vírus da Influenza A/genética , Vírus da Influenza A/patogenicidade , Influenza Humana/tratamento farmacológico , Influenza Humana/virologia , Camundongos , Camundongos Endogâmicos BALB C , Mutagênese Sítio-Dirigida , Neuraminidase/antagonistas & inibidores , Neuraminidase/metabolismo , Oseltamivir , Análise de Sequência de DNA , Replicação ViralRESUMO
The epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases have been implicated in the development, progression, and severity of several human cancers and are attractive targets for therapeutic intervention. SU11925 was developed as a small molecule inhibitor of the tyrosine kinase activity of both EGFR and HER-2. In cellular assays, SU11925 exhibited similar potency against EGFR and HER-2, inhibiting EGF-stimulated EGFR autophosphorylation in A431 (human epidermoid carcinoma) cells with an IC(50) of 30 nM and HER-2 phosphorylation in SK-OV-3TP5 (human ovarian carcinoma) cells with an IC(50) of 38 nM. In contrast to its similar activity against the two targets in cellular assays, approximately 10-fold higher plasma concentrations of SU11925 were required to inhibit HER-2 phosphorylation in HER-2-overexpressing tumors compared with EGFR phosphorylation in EGFR-overexpressing tumors in vivo. Consistent with the proposed mechanism of action of this inhibitor, SU11925 inhibited the s.c. growth of EGFR- and HER-2-dependent tumors in athymic mice at doses that produced substantial inhibition of target receptor phosphorylation in vivo. An unexpected finding from these studies was that higher plasma concentrations of SU11925 were required to inhibit EGFR phosphorylation in vivo in tumors that also express high levels of HER-2 than in tumors that express EGFR alone. This observation, which suggests that it is more difficult to inhibit EGFR phosphorylation in vivo in cells that express high levels of HER-2, was confirmed with ZD1839 (Iressa), a selective EGFR inhibitor that also targets the tyrosine kinase catalytic site. The potential clinical implications of this observation are discussed.
Assuntos
Receptores ErbB/metabolismo , Regulação Neoplásica da Expressão Gênica/fisiologia , Genes erbB-2 , Piperazinas/farmacologia , Piperazinas/uso terapêutico , Pirimidinas/farmacologia , Pirimidinas/uso terapêutico , Quinazolinas/farmacologia , Animais , Antineoplásicos/farmacologia , Carcinoma de Células Escamosas , Receptores ErbB/antagonistas & inibidores , Feminino , Gefitinibe , Humanos , Camundongos , Camundongos Nus , Neoplasias Ovarianas , Fosforilação , Receptor ErbB-2 , Transplante Heterólogo , Células Tumorais CultivadasRESUMO
Angiogenesis, or the sprouting of new blood vessels, is a central process in the growth of solid tumors. For many cancers, the extent of vascularization of a tumor is a negative prognostic indicator signifying aggressive disease and increased potential for metastasis. Recent efforts to understand the molecular basis of tumor-associated angiogenesis have identified several potential therapeutic targets, including the receptor tyrosine kinases for the angiogenic factor vascular endothelial growth factor (VEGF). Here we review the approach taken at SUGEN, Inc. to discover and develop small molecule inhibitors of receptor tyrosine kinases as anti-angiogenic agents. We focus on SU5416, a selective inhibitor of VEGF receptors that is currently in clinical development for the treatment of advanced malignancies. Its biochemical, biological and pharmacological properties are reviewed and clinical implications discussed.
Assuntos
Inibidores da Angiogênese/farmacologia , Antineoplásicos/farmacologia , Inibidores Enzimáticos/farmacologia , Indóis/farmacologia , Pirróis/farmacologia , Receptores Proteína Tirosina Quinases/antagonistas & inibidores , Receptores de Fatores de Crescimento/antagonistas & inibidores , Animais , Humanos , Receptores de Fatores de Crescimento do Endotélio VascularRESUMO
As part of our continuing work in the area of influenza neuraminidase inhibitors, a series of C3-aza inhibitors possessing a cyclic amine side chain was synthesized and evaluated for influenza neuraminidase inhibitory activity. Analogues possessing a six-, seven- and eight-membered ring, 4c-e, respectively, at the C3 position exhibited excellent influenza B neuraminidase inhibition.
Assuntos
Antivirais/química , Inibidores Enzimáticos/química , Vírus da Influenza A/efeitos dos fármacos , Vírus da Influenza B/efeitos dos fármacos , Neuraminidase/antagonistas & inibidores , Aminas/química , Antivirais/síntese química , Antivirais/farmacologia , Cristalografia por Raios X , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacologia , Humanos , Vírus da Influenza A/enzimologia , Vírus da Influenza B/enzimologiaRESUMO
SU5416, a selective inhibitor of the tyrosine kinase activity of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR, is currently in Phase III clinical trials for the treatment of advanced malignancies. In cellular assays, SU5416 inhibits the VEGF-dependent mitogenic/proliferative response of human umbilical vein endothelial cells (HUVECs). In tumor xenograft models, SU5416 inhibits the growth of tumors from a variety of origins by inhibiting tumor angiogenesis. In three different human tumor xenograft models, infrequent (once or twice a week) administration of SU5416 is efficacious despite the fact that it has a short plasma half-life (30 min), which suggests that SU5416 has long-lasting inhibitory activity in vivo. The goal of the present study was to determine the basis for the prolonged activity of SU5416. The results indicate that a short (3 h) exposure to 5 microM SU5416 (to mimic plasma levels of the compound as measured in patients who were receiving SU5416 therapy) produced long-lasting (at least 72 h) inhibition of the VEGF-dependent proliferation of HUVECs in culture, which indicate that SU5416 has long-lasting inhibitory activity in vitro as well as in vivo. SU5416 treatment of HUVECs did not affect surface expression of Flk-1/KDR or the affinity of the receptor for VEGF. Instead, the durability of the in vitro activity of SU5416 was shown to be attributable to its long-lasting ability to specifically inhibit VEGF-dependent phosphorylation of Flk-1/KDR and subsequent downstream signaling, although SU5416 is not an irreversible inhibitor of Flk-1/KDR tyrosine kinase activity. The long-lasting inhibition of cellular responses to VEGF was attributable to the accumulation of SU5416 in cells, as shown using radiolabeled compound, such that inhibitory cellular concentrations of SU5416 are maintained long after the removal of the compound from the medium. The long-lasting inhibitory activity of SU5416 in vitro is consistent with the finding that SU5416 has demonstrated evidence of biological activity in clinical studies when administered twice a week despite a short plasma half-life.
Assuntos
Inibidores da Angiogênese/farmacocinética , Indóis/farmacocinética , Neovascularização Patológica , Pirróis/farmacocinética , Receptores Proteína Tirosina Quinases/metabolismo , Receptores de Fatores de Crescimento/metabolismo , Células 3T3 , Animais , Divisão Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Separação Celular , Células Cultivadas , Meios de Cultura Livres de Soro/metabolismo , Relação Dose-Resposta a Droga , Endotélio Vascular/citologia , Endotélio Vascular/efeitos dos fármacos , Epitopos , Feminino , Citometria de Fluxo , Humanos , Cinética , Camundongos , Camundongos Nus , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Transplante de Neoplasias , Fosforilação/efeitos dos fármacos , Ligação Proteica/efeitos dos fármacos , Proteínas Tirosina Quinases/metabolismo , Receptores Proteína Tirosina Quinases/antagonistas & inibidores , Receptores Proteína Tirosina Quinases/biossíntese , Receptores de Fatores de Crescimento/antagonistas & inibidores , Receptores de Fatores de Crescimento/biossíntese , Receptores de Fatores de Crescimento do Endotélio Vascular , Transdução de Sinais/efeitos dos fármacos , Fatores de Tempo , Células Tumorais Cultivadas , Cordão Umbilical/citologia , Cordão Umbilical/efeitos dos fármacosRESUMO
The total synthesis for the determination of the absolute stereochemistry of a GS 4104 metabolite 3 is described. In addition, the influenza neuraminidase inhibitory activity of 3 and related intermediates are reported.
Assuntos
Aminas/síntese química , Antivirais/síntese química , Neuraminidase/antagonistas & inibidores , Orthomyxoviridae/enzimologia , Acetamidas/química , Acetamidas/farmacologia , Aminas/farmacologia , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacologia , Ésteres/síntese química , Conformação Molecular , Estrutura Molecular , Oseltamivir , Pró-Fármacos/química , Pró-Fármacos/metabolismoRESUMO
Influenza virus neuraminidase (NA) catalyses the cleavage of sialic acid residues terminally linked to glycoproteins and glycolipids and plays an important role in the replication of the virus. Recently, several potent NA inhibitors have been synthesized based on the rational design of mimicking the transition state of the sialic acid cleavage. Zanamivir and oseltamivir (GS 4104, the prodrug of GS 4071) have emerged as promising influenza NA inhibitors for the treatment and prophylaxis of human influenza virus infection. This review describes the recent work toward the discovery and development of influenza NA inhibitors.
Assuntos
Antivirais/farmacologia , Inibidores Enzimáticos/farmacologia , Neuraminidase/antagonistas & inibidores , Orthomyxoviridae/efeitos dos fármacos , Animais , Antivirais/química , Desenho de Fármacos , Inibidores Enzimáticos/síntese química , Humanos , Neuraminidase/química , Conformação ProteicaRESUMO
Nephrotoxicity is the dose-limiting clinical adverse effect of cidofovir and adefovir, two potent antiviral therapeutics. Because renal uptake likely plays a role in the etiology of cidofovir- and adefovir-associated nephrotoxicity, we attempted to identify a renal transporter capable of interacting with these therapeutics. A cDNA clone was isolated from a human renal library and designated human organic anion transporter 1 (hOAT1). Northern analysis detected a specific 2.5-kilobase pair hOAT1 transcript only in human kidney. However, reverse transcription-polymerase chain reaction revealed hOAT1 expression in human brain and skeletal muscle, as well. Immunoblot analysis of human kidney cortex demonstrated that hOAT1 is an 80- to 90-kilodalton heterogeneous protein modified by abundant N-glycosylation. Xenopus laevis oocytes expressing hOAT1 supported probenecid-sensitive uptake of [(3)H]p-aminohippurate (K(m) = 4 microM), which was trans-stimulated in oocytes preloaded with glutarate. Importantly, both hOAT1 and rat renal organic anion transporter 1 (rROAT1) mediated saturable, probenecid-sensitive uptake of cidofovir, adefovir, and other nucleoside phosphonate antivirals. The affinity of hOAT1 toward cidofovir and adefovir (K(m) = 46 and 30 microM, respectively) was 5- to 9-fold higher compared with rROAT1 (K(m) = 238 and 270 microM, respectively). These data indicate that hOAT1 may significantly contribute to the accumulation of cidofovir and adefovir in renal proximal tubules and, thus, play an active role in the mechanism of nephrotoxicity associated with these antiviral therapeutics.
Assuntos
Adenina/análogos & derivados , Antivirais/metabolismo , Proteínas de Transporte/genética , Citosina/análogos & derivados , Rim/efeitos dos fármacos , Organofosfonatos , Compostos Organofosforados/metabolismo , Adenina/metabolismo , Adenina/farmacologia , Sequência de Aminoácidos , Animais , Proteínas de Transporte de Ânions , Antivirais/farmacologia , Sequência de Bases , Transporte Biológico , Proteínas de Transporte/metabolismo , Cidofovir , Clonagem Molecular , Citosina/metabolismo , Citosina/farmacologia , DNA Complementar/análise , Humanos , Immunoblotting , Rim/metabolismo , Dados de Sequência Molecular , Nucleosídeos/metabolismo , Compostos Organofosforados/farmacologia , RatosRESUMO
1,4,5,6-Tetrahydropyridazine derivative 15 and its C-5 epimer 19, which possessed side chains similar to GS4071, were synthesized via a hetero Diels-Alder reaction, and evaluated as influenza neuraminidase inhibitors. Compounds 15 and 19 exhibited a microM range of influenza neuraminidase inhibitory activity.
Assuntos
Inibidores Enzimáticos/síntese química , Vírus da Influenza A/efeitos dos fármacos , Vírus da Influenza B/efeitos dos fármacos , Neuraminidase/antagonistas & inibidores , Piridazinas/síntese química , Piridazinas/farmacologia , Cristalografia por Raios X , Vírus da Influenza A/enzimologia , Vírus da Influenza B/enzimologia , Concentração Inibidora 50 , Espectroscopia de Ressonância Magnética , Modelos Químicos , Modelos MolecularesRESUMO
An oral prodrug of GS 4071, a potent and selective inhibitor of influenza neuraminidases, is currently under clinical development for the treatment and prophylaxis of influenza virus infections in humans. To investigate the potential development of resistance during the clinical use of this compound, variants of the human influenza A/Victoria/3/75 (H3N2) virus with reduced susceptibility to the neuraminidase inhibitor GS 4071 were selected in vitro by passaging the virus in MDCK cells in the presence of inhibitor. After eight passages, variants containing two amino acid substitutions in the hemagglutinin (A28T in HA1 and R124M in HA2) but no changes in the neuraminidase were isolated. These variants exhibited a 10-fold reduction in susceptibility to GS 4071 and zanamivir (GG167) in an in vitro plaque reduction assay. After 12 passages, a second variant containing these hemagglutinin mutations and a Lys substitution for the conserved Arg292 of the neuraminidase was isolated. The mutant neuraminidase enzyme exhibited high-level (30,000-fold) resistance to GS 4071, but only moderate (30-fold) resistance to zanamivir and 4-amino-Neu5Ac2en, the amino analog of zanamivir. The mutant enzyme had weaker affinity for the fluorogenic substrate 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid and lower enzymatic activity compared to the wild-type enzyme. The viral variant containing the mutant neuraminidase did not replicate as well as the wild-type virus in culture and was 10,000-fold less infectious than the wild-type virus in a mouse model. These results suggest that although the R292K neuraminidase mutation confers high-level resistance to GS 4071 in vitro, its effect on viral virulence is likely to render this mutation of limited clinical significance.
Assuntos
Acetamidas/farmacologia , Antivirais/farmacologia , Inibidores Enzimáticos/farmacologia , Vírus da Influenza A/enzimologia , Neuraminidase/antagonistas & inibidores , Animais , Linhagem Celular , Embrião de Galinha , Cães , Resistência Microbiana a Medicamentos , Feminino , Hemaglutininas/biossíntese , Hemaglutininas/genética , Vírus da Influenza A/efeitos dos fármacos , Vírus da Influenza A/patogenicidade , Rim/citologia , Camundongos , Camundongos Endogâmicos BALB C , Mutação , Neuraminidase/genética , Oseltamivir , Ensaio de Placa Viral , Virulência , Replicação Viral/efeitos dos fármacosRESUMO
A series of influenza neuraminidase inhibitors with the cyclohexene scaffold containing lipophilic side chains have been synthesized and evaluated for influenza A and B neuraminidase inhibitory activity. The size and geometry of side chains have been modified systematically in order to investigate structure-activity relationships of this class of compounds. The X-ray crystal structures of several analogues complexed with neuraminidase revealed that the lipophilic side chains bound to the hydrophobic pocket consisted of Glu276, Ala246, Arg224, and Ile222 of the enzyme active site. The structure-activity relationship studies of this series have also demonstrated remarkably different inhibitory potency between influenza A and B neuraminidase. This indicated that the lipophilic side chains had quite different hydrophobic interactions with influenza A and B neuraminidase despite their complete homology in the active site. Influenza B neuraminidase appeared to be much more sensitive toward the increased steric bulkiness of inhibitors compared to influenza A neuraminidase. From the extensive structure-activity relationship investigation reported in this article, GS 4071 emerged as one of the most potent influenza neuraminidase inhibitors against both influenza A and B strains.
Assuntos
Acetamidas/farmacologia , Antivirais/farmacologia , Inibidores Enzimáticos/farmacologia , Vírus da Influenza A/enzimologia , Vírus da Influenza B/enzimologia , Neuraminidase/antagonistas & inibidores , Acetamidas/química , Antivirais/química , Cristalografia por Raios X , Inibidores Enzimáticos/química , Modelos Moleculares , Estrutura Molecular , Oseltamivir , Relação Estrutura-AtividadeAssuntos
Aciclovir/farmacologia , Antivirais/farmacologia , Citosina/análogos & derivados , Resistência a Múltiplos Medicamentos , Foscarnet/farmacologia , Herpes Simples/tratamento farmacológico , Herpesvirus Humano 1/efeitos dos fármacos , Organofosfonatos , Compostos Organofosforados/farmacologia , Adulto , Cidofovir , Citosina/farmacologia , Resistência Microbiana a Medicamentos , Herpes Simples/patologia , Herpes Simples/fisiopatologia , Humanos , Injeções Intravenosas , Leucemia Mieloide Aguda/complicações , MasculinoRESUMO
We have recently described GS 4071, a carbocyclic transition-state analog inhibitor of the influenza virus neuraminidase, which has potent inhibitory activity comparable to that of 4-guanidino-Neu5Ac2en (GG167; zanamivir) when tested against influenza A virus replication and neuraminidase activity in vitro. We now report that GS 4071 is active against several strains of influenza A and B viruses in vitro and that oral GS 4104, an ethyl ester prodrug which is converted to GS 4071 in vivo, is active in the mouse and ferret models of influenza virus infection. Oral administration of 10 mg of GS 4104 per kg of body weight per day caused a 100-fold reduction in lung homogenate viral titers and enhanced survival in mice infected with influenza A or B viruses. In ferrets, a 25-mg/kg dose of GS 4104 given twice daily reduced peak viral titers in nasal washings and eliminated constitutional responses to influenza virus infection including fever, increased nasal signs (sneezing, nasal discharge, mouth breathing), and decreased activity. Consistent with our demonstration that the parent compound is highly specific for influenza virus neuraminidases, no significant drug-related toxicity was observed after the administration of oral dosages of GS 4104 of up to 800 mg/kg/day for 14 days in nonclinical toxicology studies with rats. These results indicate that GS 4104 is a novel, orally active antiviral agent with the potential to be used for the prophylaxis and treatment of influenza A and B virus infections.
Assuntos
Acetamidas/farmacologia , Antivirais/farmacologia , Vírus da Influenza A/efeitos dos fármacos , Vírus da Influenza B/efeitos dos fármacos , Neuraminidase/antagonistas & inibidores , Infecções por Orthomyxoviridae/prevenção & controle , Pró-Fármacos/farmacologia , Acetamidas/administração & dosagem , Acetamidas/metabolismo , Administração Oral , Aminas/administração & dosagem , Aminas/metabolismo , Aminas/farmacologia , Animais , Antivirais/administração & dosagem , Antivirais/metabolismo , Modelos Animais de Doenças , Feminino , Furões , Guanidinas , Vírus da Influenza A/crescimento & desenvolvimento , Vírus da Influenza B/crescimento & desenvolvimento , Camundongos , Camundongos Endogâmicos BALB C , Neuraminidase/efeitos dos fármacos , Oseltamivir , Pró-Fármacos/administração & dosagem , Pró-Fármacos/metabolismo , Piranos , Ratos , Ratos Sprague-Dawley , Ácidos Siálicos/administração & dosagem , Ácidos Siálicos/metabolismo , Ácidos Siálicos/farmacologia , Replicação Viral/efeitos dos fármacos , ZanamivirRESUMO
GS 4071 is a potent carbocyclic transition-state analog inhibitor of influenza virus neuraminidase with activity against both influenza A and B viruses in vitro. GS 4116, the guanidino analog of GS 4071, is a 10-fold more potent inhibitor of influenza virus replication in tissue culture than GS 4071. In this study we determined the oral bioavailabilities of GS 4071, GS 4116, and their respective ethyl ester prodrugs in rats. Both parent compounds and the prodrug of the guanidino analog exhibited poor oral bioavailability (2 to 4%) and low peak concentrations in plasma (Cmaxs; Cmax <0.06 microg/ml). In contrast, GS 4104, the ethyl ester prodrug of GS 4071, exhibited good oral bioavailability (35%) as GS 4071 and high Cmaxs of GS 4071 (Cmax = 0.47 microg/ml) which are 150 times the concentration necessary to inhibit influenza virus neuraminidase activity by 90%. The bioavailability of GS 4104 as GS 4071 was also determined in mice (30%), ferrets (11%), and dogs (73%). The plasma of all four species exhibited high, sustained concentrations of GS 4071 such that at 12 h postdosing the concentrations of GS 4071 in plasma exceeded those necessary to inhibit influenza virus neuraminidase activity by 90%. These results demonstrate that GS 4104 is an orally bioavailable prodrug of GS 4071 in animals and that it has the potential to be an oral agent for the prevention and treatment of influenza A and B virus infections in humans.
Assuntos
Acetamidas/farmacocinética , Aminas/farmacocinética , Antivirais/farmacocinética , Neuraminidase/efeitos dos fármacos , Infecções por Orthomyxoviridae/metabolismo , Orthomyxoviridae/efeitos dos fármacos , Pró-Fármacos/farmacocinética , Acetamidas/administração & dosagem , Acetamidas/sangue , Administração Oral , Aminas/administração & dosagem , Aminas/sangue , Animais , Antivirais/administração & dosagem , Antivirais/sangue , Disponibilidade Biológica , Cães , Relação Dose-Resposta a Droga , Furões , Hidrólise , Camundongos , Neuraminidase/antagonistas & inibidores , Oseltamivir , Pró-Fármacos/administração & dosagem , Pró-Fármacos/metabolismo , Ratos , Ratos Sprague-Dawley , Fatores de TempoRESUMO
Influenza continues to be a major health concern and there is always the threat of a pandemic due to the emergence of a viral strain new to the human population, as exemplified by the avian influenza A/H5N1 virus which was responsible for six deaths in Hong Kong last year. Data reported in the past year, based on in-vitro, in-vivo (animal) and clinical studies, suggest that a new class of antiviral compounds targeting the viral neuraminidase is likely to be useful for the treatment and prevention of influenza virus infections in humans.
RESUMO
The recent reports from Hong Kong of an avian influenza virus which caused the death of six people has served to remind us of the constant threat of pandemics posed by influenza. Recently, structure-based drug design has resulted in the discovery of a new class of antiviral agents which specifically target the influenza virus neuraminidase. Two neuraminidase inhibitors are currently undergoing clinical evaluation for the prevention and treatment of influenza virus infection in man. Here we review the results of in vitro and in vivo studies relating to the potential development of resistance to this new class of compounds.
RESUMO
The synthesis and influenza neuraminidase inhibitory activity of a new series of C3-aza carbocyclic neuraminidase inhibitors are described. Analogues 3c and 3j, bearing a 3-pentyl group, exhibit influenza A inhibitory activities comparable to that of 1.
Assuntos
Antivirais/síntese química , Compostos Aza/síntese química , Inibidores Enzimáticos/síntese química , Neuraminidase/antagonistas & inibidores , Orthomyxoviridae/efeitos dos fármacos , Antivirais/farmacologia , Compostos Aza/farmacologia , Inibidores Enzimáticos/farmacologia , Neuraminidase/química , Orthomyxoviridae/enzimologia , Relação Estrutura-AtividadeRESUMO
Cidofovir (HPMPC) [1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]-cytosine] is an acyclic nucleotide analog with potent and selective activity against herpesviruses. The prodrug, cyclic HPMPC (cHPMPC) [1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl) methyl]cytosine], has antiviral activity similar to that of the parent compound but exhibits reduced toxicity in animal models. cHPMPC is converted to cidofovir by a cellular cyclic CMP phosphodiesterase (EC 3.1.4.37) which hydrolyzes a variety of substrates, including adenosine 3',5'-cyclic monophosphate (cAMP) and cytidine 3',5'-cyclic monophosphate (cCMP). The K(m) and Vmax values for hydrolysis of cHPMPC by cCMP phosphodiesterase purified from human liver are 250 microM and 0.66 nmol.min-1.unit-1, respectively. These values are similar to the K(m) and Vmax values for cAMP (23 microM and 1.16 nmol.min-1.unit-1, respectively) and cCMP (75 microM and 2.32 nmol.min-1.unit of enzyme-1, respectively). The catalytic efficiency (Vmax/K(m) ratio) of this enzyme for the cHPMPC substrate is only 10- to 20-fold lower than those for the natural cyclic nucleotides, indicating that cHPMPC is a viable intracellular substrate for the human enzyme. Kinetic analysis indicates that cHPMPC, cAMP, and cCMP are competitive with respect to each other and that they are hydrolyzed by the same enzyme. cHPMPC is hydrolyzed to cidofovir in all primary human cell systems tested, including those derived from target organs that might be infected in patients with human cytomegalovirus (HCMV) disease. Importantly, hydrolysis of cHPMPC is not diminished in cells infected with HCMV.
Assuntos
Antivirais/metabolismo , Citosina/análogos & derivados , Organofosfonatos , Compostos Organofosforados/metabolismo , Diester Fosfórico Hidrolases/metabolismo , Pró-Fármacos/metabolismo , 2',3'-Nucleotídeo Cíclico 3'-Fosfodiesterase , Animais , Células CACO-2 , Linhagem Celular , Cromatografia de Afinidade , Cromatografia em Gel , Cromatografia por Troca Iônica , Cidofovir , Citosina/metabolismo , Citosol/enzimologia , Fibroblastos , Humanos , Cinética , Fígado/enzimologia , Diester Fosfórico Hidrolases/isolamento & purificação , SuínosRESUMO
The design, synthesis, and in vitro evaluation of the novel carbocycles as transition-state-based inhibitors of influenza neuraminidase (NA) are described. The double bond position in the carbocyclic analogues plays an important role in NA inhibition as demonstrated by the antiviral activity of 8 (IC50 = 6.3 microM) vs 9 (IC50 > 200 microM). Structure-activity studies of a series of carbocyclic analogues 6a-i identified the 3-pentyloxy moiety as an apparent optimal group at the C3 position with an IC50 value of 1 nM for NA inhibition. The X-ray crystallographic structure of 6h bound to NA revealed the presence of a large hydrophobic pocket in the region corresponding to the glycerol subsite of sialic acid. The high antiviral potency observed for 6h appears to be attributed to a highly favorable hydrophobic interaction in this pocket. The practical synthesis of 6 starting from (-)-quinic acid is also described.
Assuntos
Acetamidas/síntese química , Antivirais/síntese química , Antivirais/farmacologia , Ácidos Carboxílicos/síntese química , Cicloexanos/síntese química , Vírus da Influenza A/efeitos dos fármacos , Neuraminidase/antagonistas & inibidores , Ácidos Siálicos/síntese química , Acetamidas/farmacologia , Animais , Sítios de Ligação/efeitos dos fármacos , Ácidos Carboxílicos/farmacologia , Linhagem Celular , Cristalografia por Raios X , Cicloexanos/farmacologia , Cicloexenos , Modelos Animais de Doenças , Desenho de Fármacos , Inibidores Enzimáticos/síntese química , Interações Hidrofóbicas e Hidrofílicas , Vírus da Influenza A/enzimologia , Vírus da Influenza A/crescimento & desenvolvimento , Ácido Quínico/química , Ácidos Siálicos/farmacologia , Relação Estrutura-Atividade , Ensaio de Placa ViralRESUMO
PMEA [9-[2-(phosphonomethoxy)ethyl]adenine; adefovir] has shown anti-cytomegalovirus activity in animal models and in preliminary human trials. PMEA diphosphate (PMEApp), the active antiviral metabolite of PMEA, is a potent inhibitor of human cytomegalovirus (HCMV) DNA polymerase. PMEA is efficiently taken up and phosphorylated to PMEApp in numerous human cell lines. In vitro replication of wild type and drug resistant HCMV clinical isolates is effectively inhibited by PMEA. PMEA in combination with other anti-HCMV agents shows additive inhibition of HCMV replication.